LONDON (Alliance News) - Akers Biosciences Inc said Tuesday that it received an "overwhelmingly positive" response to the introduction of its two new breath tests at the World Congress on Anti-Aging Medicine, and it led to "several hundred" reservations for products when commercial production begins in the third quarter of the year.
The products, called BreathScan OxiCheck and BreathScan KetoChek, are designed to allow users to monitor trends in critical metabolic processes.
Since the congress, which took place in May, the company has established several strategic partnerships to advance the commercialisation of the products, it said.
"We believe that the response to the Akers Wellness product introduction sends a clear message that there is a strong demand for efficiently delivered personalized health information," said Co-Founder and Executive Chairman Raymond Akers Jr in a statement.
Shares in Akers are untraded Tuesday. It last closed at 260.00 pence.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.